爱优特®(呋喹替尼/fruquintinib)获纳入联合达伯舒®(信迪利单抗注射液)用于治疗既往系统性抗肿瘤治疗 后失败且不适合进行根治性手术治疗或根治性放疗的晚期错配修复完整(pMMR)子宫内膜癌患者。爱优 特®还获续约用于治疗既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或 不适合接受抗血管内皮生长因子(VEGF)治疗、抗表皮生长因子受体(EGFR)治疗(RAS野生型)的转移性 结直肠癌患者。 格隆汇12月8日丨和黄医药(00013.HK)宣布，经过与中国国家医疗保障局("国家医保局")的医保续约，爱 优特®(ELUNATE®)、沃瑞沙®(ORPATHYS®)和苏泰达®(SULANDA®)将继续获纳入自2026年1月1日起 生效的新版《国家基本医疗保险、工伤保险和生育保险药品目录》("国家医保药品目录")。此外，达唯 珂®(TAZVERIK®)获纳入首版国家商业健康保险创新药品目录(简称"商保创新药目录")。 沃瑞沙®(赛沃替尼/savolitinib)获纳入用于治疗携带间质-上皮转化因子(MET)外显子14跳变的局部晚期 或转移性非小细胞肺癌成人患者。 苏泰达®(凡替尼/suruf ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表⽰，概不 對因本公告全部或任何部分內容⽽產⽣或因倚賴該等內容⽽引致的任何損失承擔任何責任。 ⾃願性公告 和⿈醫藥宣佈商業化產品的國家醫保藥品⽬錄覆蓋範圍進⼀步擴⼤ 並獲納⼊⾸版國家商保創新藥⽬錄 和⿈醫藥（中國）有限公司（簡稱「和⿈醫藥」或「HUTCHMED」）今⽇宣佈，經過與中國國家醫療保障局（「國 家醫保局」）的醫保續約，愛優特®（ELUNATE®）、沃瑞沙®（ORPATHYS®）和蘇泰達®（SULANDA®）將繼續獲納 ⼊⾃2026年1⽉1⽇起⽣效的新版《國家基本醫療保險、⼯傷保險和⽣育保險藥品⽬錄》（「國家醫保藥品⽬錄」）。 此外，達唯珂®（TAZVERIK®）獲納⼊⾸版國家商業健康保險創新藥品⽬錄（簡稱「商保創新藥⽬錄」)。 愛優特®（呋喹替尼/ fruquintinib）獲納⼊聯合達伯舒®（信迪利單抗注射液）⽤於治療既往系統性抗腫瘤治療後 失敗且不適合進⾏根治性⼿術治療或根治性放療的晚期錯配修復完整（pMMR）⼦宮內膜癌患者。愛優特®還獲續 約⽤於治療既往接受過氟尿嘧啶類、奧沙利鉑和 ...

Core Viewpoint - HUTCHMED has successfully renewed contracts with the China National Healthcare Security Administration (NHSA), ensuring the inclusion of its drugs ELUNATE, ORPATHYS, and SULANDA in the updated National Reimbursement Drug List (NRDL) effective January 1, 2026, and the addition of TAZVERIK to the National Commercial Health Insurance Innovative Drug List [1][4]. Group 1: Drug Inclusion and Details - ELUNATE (fruquintinib) is included for treating advanced endometrial cancer with pMMR tumors and metastatic colorectal cancer patients who have undergone prior chemotherapy [2]. - ORPATHYS (savolitinib) is included for adult patients with locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping alteration [3]. - SULANDA (surufatinib) is renewed for treating unresectable, locally advanced or metastatic, progressive non-functional well-differentiated neuroendocrine tumors [3]. - TAZVERIK (tazemetostat) is included in the Commercial Insurance Drug List for adult patients with relapsed or refractory follicular lymphoma with EZH2 mutation [4]. Group 2: Reimbursement Framework - The new Commercial Insurance Drug List, established by the NHSA, focuses on innovative medicines with significant clinical value, enabling reimbursement through various commercial health insurance products [4]. - As of the end of 2024, approximately 1.33 billion people in China had basic medical insurance coverage, representing around 95% of the population, highlighting the government's commitment to improving drug affordability [5]. Group 3: Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [10]. - The company has successfully brought its first three medicines to market in China, with one also approved globally [10].

"这批机器人就要发往均胜电子的汽车零部件工厂，过亿元采购合同的首批机器人产品即将交付商用。"智元机器人首席营销官（CMO）邱恒兴奋地对智通 财经介绍说。 谁能想到，这家两年多前在浦东诞生的初创团队，如今已成为人形机器人商业化领军者。智元机器人的成长轨迹，正是浦东引领区过去五年发展的缩影。 2021年，中共中央、国务院印发《关于支持浦东新区高水平改革开放打造社会主义现代化建设引领区的意见》，标志着浦东新区立足新发展阶段，肩负起新 使命，踏上了更高水平改革开放的新征程。 如今，浦东引领区建设正式进入第五个年头。浦东交出了一份亮眼的发展答卷：2024年地区生产总值达1.78万亿元，较2020年增长近35%；2025年前三季度 生产总值同比增长6%；人均生产总值达4.3万美元，超过意大利水平；全员劳动生产率达60.6万元/人；城乡居民人均收入达9.5万元。 在这片充满活力的热土上，一批企业与平台扎根生长，用从初创到领跑、从本土到全球的成长轨迹，诠释了浦东引领区建设五年来的蓬勃活力。 高端产业集群崛起 智通财经记者 | 方卓然 智通财经编辑 | 庄键 2025年10月的一个清晨，新一代工业级交互式具身作业机器人"精灵G ...

截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 和黃醫藥（中國）有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00013 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,500,000,000 | USD | | 0.1 | USD | | 150,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 1,500,000,000 | USD | | 0.1 | USD | | 150,000,000 | 本月底法定/註冊股本總額： USD 150,000,000 股份發行人及根據《上市規則》 ...

Core Viewpoint - Hutchison China MediTech Limited (HCM) announced the latest updates on several research studies of its self-developed compounds, which will be presented at major upcoming oncology conferences in 2025 [1] Group 1: Upcoming Presentations - Results from the first human clinical trial of the anti-CD47 monoclonal antibody HMPL-A83 for the treatment of advanced solid tumors will be presented at the ESMO Asia Congress in Singapore from December 5 to 7, 2025 [1] - The results of the FRUSICA-2 registration study's Phase II portion, which examines fruquintinib in combination with sintilimab for second-line treatment of locally advanced or metastatic renal cell carcinoma, will also be shared at the same ESMO Asia Congress [1] - Additionally, results from a Phase II/III study of surufatinib combined with camrelizumab and chemotherapy for first-line treatment of metastatic pancreatic cancer will be presented at the conference [1]

Core Viewpoint - Hutchison China MediTech Limited (HCM) announced the latest and updated data from several studies of its self-developed compounds, which will be presented at the European Society for Medical Oncology (ESMO) Asia Congress in Singapore and the American Society of Hematology (ASH) Annual Meeting in Orlando in December 2025 [1] Group 1: Clinical Trials and Presentations - The first human clinical trial results of the anti-CD47 monoclonal antibody HMPL-A83 for the treatment of advanced solid tumors will be presented at the 2025 ESMO Asia Congress [1] - Results from the FRUSICA-2 registration study's Phase II portion, which examines fruquintinib in combination with sintilimab for second-line treatment of locally advanced or metastatic renal cell carcinoma, will also be disclosed at the 2025 ESMO Asia Congress [1] - The Phase II portion results of a study combining surufatinib with camrelizumab and chemotherapy for first-line treatment of metastatic pancreatic cancer will be presented at the same congress [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） 自願性公告 和黃醫藥將於2025年歐洲腫瘤內科學會 (ESMO) 亞洲年會和 2025年美國血液學會 (ASH) 年會公佈臨床數據 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」或 「HUTCHMED」）今日宣佈和黃醫藥自主研發的化合物的數項研 究的最新及更新後的數據將於2025年12月5日至7日在新加坡召開的歐洲腫瘤內科學會（ESMO）亞洲年會，以及 2025年12月6日至9日在美國奧蘭多召開的美國血液學會（ASH）年會上公佈。 | 摘要標題 | 報告人/ 主要作者 報告詳情 | | | --- | --- | --- | | 奧希替尼聯合賽沃替尼用於治療EGFR突變伴MET過表達和/或奧希替尼治療後進展 | Se-Hoon Lee | 982P | | 的晚期非小細胞肺癌: S ...

Core Insights - HUTCHMED will present new and updated data from several studies at the upcoming ESMO Asia Congress 2025 and ASH Annual Meeting, showcasing its commitment to advancing cancer therapies [1][2][3] Group 1: Upcoming Presentations - A first-in-human study of HMPL-A83, an anti-CD47 monoclonal antibody, will be presented, focusing on advanced solid tumors [2] - The phase II results of the FRUSICA-2 study, evaluating the combination of fruquintinib and sintilimab for renal cell carcinoma, will also be shared [2] - Surufatinib's phase II results in combination with camrelizumab and chemotherapy for metastatic pancreatic cancer will be reported [2] Group 2: Specific Study Details - HMPL-A83 presentation details include a mini oral session on December 7, 2025, led by Ye Guo [2] - Fruquintinib's results will be presented by Shanshan Wang on December 5, 2025, in a proffered paper session [2] - Surufatinib's study will be displayed as a poster by Shukui Qin [2] Group 3: Additional Studies - Several investigator-initiated studies will also be presented, including combinations of fruquintinib with other treatments for metastatic colorectal cancer [3] - The final analysis of the ESLIM-01 study on sovleplenib for chronic primary immune thrombocytopenia will be presented at the ASH Annual Meeting [3] Group 4: Product Information - Fruquintinib is a selective oral inhibitor of VEGFRs, co-developed by HUTCHMED and Eli Lilly, marketed as ELUNATE in China [4] - HMPL-A83 is a humanized anti-CD47 monoclonal antibody that disrupts cancer cells' immune evasion [5] - Savolitinib is a selective MET tyrosine kinase inhibitor developed by AstraZeneca and HUTCHMED, marketed as ORPATHYS [6] - Surufatinib is an oral angio-immuno kinase inhibitor marketed as SULANDA in China [7] - Sovleplenib is a selective small molecule inhibitor targeting Syk, with potential applications in B-cell lymphomas [8]

Summary of the Conference Call for Hodgman Company Industry and Company Overview - The conference call pertains to Hodgman Company, a biopharmaceutical firm focused on oncology and autoimmune disease treatments, with a significant presence in both the Chinese and global markets [2][3][4]. Key Points and Arguments Product Pipeline and Performance - **Orpathys**: A carbonic anhydrase inhibitor for lung cancer, currently commercialized in China, with a Phase III clinical trial in collaboration with AstraZeneca expected to yield data in mid-2026, aiming for global approval by 2027 [2][3]. - **Cavatak**: A colorectal cancer treatment with sales of approximately $616 million in the first half of 2025, showcasing Hodgman's strength in the Chinese market and global competitiveness [3]. - **Tequila**: A top-selling oncology drug, recently approved for metastatic colorectal cancer, with expected growth driven by markets in Europe and Japan. It has received approval for endometrial cancer in China and is under investigation for second-line kidney cancer, anticipated to be approved by late 2026 [2][8]. - **SAFFRON Trial**: A Phase II clinical trial for a second-line EGFR mutation non-small cell lung cancer drug, with results expected in mid-2026. If successful, it could lead to U.S. approval around 2027, targeting patients with c-MET gene amplification [10][11]. Financial Guidance and Market Strategy - The company has adjusted its revenue guidance downward due to weak sales in the first half of 2025, attributed to increased competition and infrastructure restructuring for compliance, which has temporarily impacted sales activities [5][6]. - Despite short-term challenges, Hodgman anticipates improved performance in the second half of 2025, driven by recovery in the Chinese market [5][6]. ATTC Platform - The ATTC (Antibody-Targeted Therapy Conjugate) platform is a novel treatment modality that uses small molecule targeted drugs instead of chemical toxins, aiming to reduce toxicity and enhance selectivity. Currently in Phase I trials, it shows significant potential for future applications [4][6]. - Hodgman is actively seeking partnerships to advance the ATTC platform, with interest from multinational pharmaceutical companies [7]. Market Opportunities and Challenges - The Chinese market remains crucial for Hodgman, but competition is fierce, with lower prices and limited profit margins. The company is focusing on expanding its presence in higher-margin markets like the U.S., Europe, and Japan [5][6]. - The potential market size for the second-line EGFR mutation treatment in the U.S. and China is estimated at around $1 billion, with Hodgman aiming to capture significant market share through ongoing trials and approvals [11][12]. Other Important Insights - Hodgman has a strong balance sheet and stable revenue from its commercialized products, positioning it well for future growth [4][13]. - The company is optimistic about the ITP inhibitor project, which is expected to resubmit data in mid-2026 for potential approval in 2027, marking its entry into the autoimmune disease market [12]. This summary encapsulates the critical aspects of Hodgman Company's conference call, highlighting its product pipeline, financial outlook, strategic initiatives, and market positioning.